Addict Biology: GLP-1样药物可用于治疗酒精依赖症

2015-09-27 QQduhq 译 MedSci原创

萨尔格学院对小鼠和大鼠进行的一项新研究显示,用于治疗糖尿病和肥胖症的药物也可能有助于治疗酒精依赖症。 由于酒精依赖导致的民众死亡事件的发生是当今社会主要的健康问题和公众问题。在瑞典,国家每年用于治疗酒精依赖的花销约为450亿瑞典克朗。且近5%的成年人被诊断为酒精依赖,约300300人。且据调查,更多的人饮酒过量甚至伤身。实际上,约有15%的民众饮酒过量,在这些人中,男性每周饮酒超过14杯,女性每周



萨尔格学院对小鼠和大鼠进行的一项新研究显示,用于治疗糖尿病和肥胖症的药物也可能有助于治疗酒精依赖症。 

由于酒精依赖导致的民众死亡事件的发生是当今社会主要的健康问题和公众问题。在瑞典,国家每年用于治疗酒精依赖的花销约为450亿瑞典克朗。且近5%的成年人被诊断为酒精依赖,约300300人。且据调查,更多的人饮酒过量甚至伤身。实际上,约有15%的民众饮酒过量,在这些人中,男性每周饮酒超过14杯,女性每周饮酒超过9杯。

瑞典哥德堡大学萨尔格学院一项新研究表明,研究者发现,与GLP-1作用类似的药物可以用于治疗2型糖尿病和肥胖症,还可以用来治疗酒精依赖。干扰GLP-1因子的分泌可以用于治疗酒精依赖,这对治疗酒精依赖是一个全新的突破。

通常喝酒过后,大脑中的多巴胺分泌增多,因此饮酒者会出现兴奋感。 GLP-1样激素可抑制多巴胺的分泌,从而减少酒精带给饮酒者的愉悦感,因此饮酒者也不会过量饮酒。 

除了用于治疗糖尿病的药物会减少小鼠的饮酒量,同时也减少了小鼠饮酒的动力和欲望。同时这种药物也有助于预防戒酒者出现反弹,也解决了饮酒者出现的酒精依赖的问题。 

萨尔格学院研究员Elisabet Jerlhag说道:“ GLP-1样药物可以使30-40%饮酒量颇大的老鼠连续几个月内减少饮酒量。”

同样,GLP-1类药物不仅可以用于治疗酒精依赖症,还能用于治疗暴饮暴食。肠道分泌GLP-1激素时,民众会出现饱腹感,因此大脑反馈调节后便减少了民众的摄入量。

研究人员表示,还需要更进一步的后续研究详细明确GLP-1类药物的作用,对人体有无副作用和不良反应。除了应用于小鼠,还有望进行更进一步的试验。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858627, encodeId=91a8185862e10, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Aug 22 17:38:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917193, encodeId=1742191e193c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Feb 02 20:38:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766965, encodeId=bb341e66965c8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 26 14:38:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422692, encodeId=1801142269290, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575786, encodeId=b11d15e5786fb, content=<a href='/topic/show?id=5e1f954e563' target=_blank style='color:#2F92EE;'>#酒精依赖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95475, encryptionId=5e1f954e563, topicName=酒精依赖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5c116191457, createdName=xue8607, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=)]
    2016-08-22 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858627, encodeId=91a8185862e10, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Aug 22 17:38:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917193, encodeId=1742191e193c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Feb 02 20:38:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766965, encodeId=bb341e66965c8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 26 14:38:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422692, encodeId=1801142269290, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575786, encodeId=b11d15e5786fb, content=<a href='/topic/show?id=5e1f954e563' target=_blank style='color:#2F92EE;'>#酒精依赖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95475, encryptionId=5e1f954e563, topicName=酒精依赖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5c116191457, createdName=xue8607, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=)]
    2016-02-02 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858627, encodeId=91a8185862e10, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Aug 22 17:38:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917193, encodeId=1742191e193c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Feb 02 20:38:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766965, encodeId=bb341e66965c8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 26 14:38:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422692, encodeId=1801142269290, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575786, encodeId=b11d15e5786fb, content=<a href='/topic/show?id=5e1f954e563' target=_blank style='color:#2F92EE;'>#酒精依赖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95475, encryptionId=5e1f954e563, topicName=酒精依赖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5c116191457, createdName=xue8607, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858627, encodeId=91a8185862e10, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Aug 22 17:38:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917193, encodeId=1742191e193c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Feb 02 20:38:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766965, encodeId=bb341e66965c8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 26 14:38:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422692, encodeId=1801142269290, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575786, encodeId=b11d15e5786fb, content=<a href='/topic/show?id=5e1f954e563' target=_blank style='color:#2F92EE;'>#酒精依赖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95475, encryptionId=5e1f954e563, topicName=酒精依赖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5c116191457, createdName=xue8607, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=)]
    2015-09-29 yibei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858627, encodeId=91a8185862e10, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Mon Aug 22 17:38:00 CST 2016, time=2016-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917193, encodeId=1742191e193c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Feb 02 20:38:00 CST 2016, time=2016-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766965, encodeId=bb341e66965c8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jul 26 14:38:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422692, encodeId=1801142269290, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575786, encodeId=b11d15e5786fb, content=<a href='/topic/show?id=5e1f954e563' target=_blank style='color:#2F92EE;'>#酒精依赖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95475, encryptionId=5e1f954e563, topicName=酒精依赖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5c116191457, createdName=xue8607, createdTime=Tue Sep 29 11:38:00 CST 2015, time=2015-09-29, status=1, ipAttribution=)]

相关资讯

朱大龙:GLP-1降糖药物的临床应用共识

  肠促胰素引起的胰岛素分泌能力约占全部胰岛素分泌量的50~70%,而且这一作用具有葡萄糖浓度依赖的特点,故在调节血糖的同时,引起低血糖的风险很低。此外,GLP-1可抑制胰腺α细胞分泌胰高糖素,并有减轻体重、改善β细胞功能和在动物模型中增加β细胞量的作用,可对2型糖尿病患者的代谢异常进行多方面的调控。EMA在2013年7月25日发表GLP-1相关药物的评估报告中,目前没有证据支持GLP-1增加胰腺

ADA 2015:GLP-1类药物降低体重的奥秘——影响大脑对食物的反应

胃肠激素类药物(Gut hormone),如 GLP-1(胰高血糖素样肽 -1)受体激动剂在临床上被用于糖尿病治疗,同时也具有降低体重的作用。研究人员一直在试图揭示其作用机制。6月9日,第 75 届美国糖尿病学会科学年会(ADA 2015)公布的一项研究结果阐述了GLP-1 受体激动剂可改变大脑对食物的反应,这或许能够降低患者对食物的渴望以及增加进食过程中的满足感。    &n

Diabetes Care:GLP-1受体激动剂可以作为青少年的成年发病型糖尿病(MODY)3型的替代治疗

HNF1A糖尿病[青少年的成年发病型糖尿病(MODY)3型]患者通常使用磺脲类药物治疗,面临低血糖频发风险。第2项研究是一项双盲、随机、交叉试验,探索GLP-1受体激动剂能否作为有效的替代选择。研究纳入的16例HNF1A糖尿病患者随机接受格列美脲(n=8)或利拉鲁肽 (n=8)治疗6周。 结果表明,两组患者的空腹血糖(FPG,主要疗效终点)和餐后血糖水平均较基线显著下降,胰岛素和C肽反应提

胰高血糖素样肽-1(GLP-1)保护胰岛β细胞相关分子机制的研究进展

  胰高血糖素样肽-1(Glucagon-like peptide-1,GLP-1)是肠道L细胞分泌的一种重要的肠促胰岛素.大量研究表明,除刺激胰岛素分泌外,GLP-1可通过促进胰岛β细胞增殖,抑 制β细胞凋亡而增加胰岛β细胞量,本文就其相关分子信号转导机制进行综述. 胰高血糖素样肽-1保护胰岛β细胞相关分子机制的研究进展.pdf

Diabetes:GLP-1五肽小分子可抑制肥胖

目前,因肥胖而导致的糖尿病在全世界范围内越来越普遍流行。近日,美国科学家在国际学术期刊Diabetes在线发表了一项最新科研进展,他们发现来源于胰高血糖素样肽GLP-1氨基端的五肽能够促进基础能量消耗,促进饮食诱导的小鼠模型抵抗肥胖发生,并能改善代谢,具有重要开发价值。 研究人员发现的这种五肽小分子能够通过增加基础能量消耗、抑制肥胖过程的发展,改善饮食诱导的肥胖小鼠的胰岛素敏感性、糖尿病

Neuropharmacology:GLP-1受体可能是慢性疼痛的关键靶点

上海交通大学药学院王永祥带领的科研团队找到慢性疼痛克星。5月7日,研究团队对外首次发布了发现脊髓GLP-1受体可在慢性疼痛中产生有效镇痛作用的消息,新发现的镇痛新靶点,能对肿瘤癌症、糖尿病等疼痛抑制率达到60%-90%。   慢性疼痛家族包括头疼、牙疼,还有炎症痛、肿瘤癌症痛、神经源性痛、糖尿病疼痛和腰背痛等。尤其是糖尿病患者中25%存在神经性疼痛;肿瘤癌症患者,常常也伴有长期的、不